Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Oct 15, 2005 (Vol. 25, No. 18)

The Sanger Institute: Catalogue of Somatic Mutations in Cancer

  • Mutation info
  • Focus a bit vague
Recognizing that cancer arises from mutations in DNA, the Sanger Institute's Catalogue of Somatic Mutations in Cancer (COSMIC) "stores and displays" somatic mutation information relating to human cancer. The site's information page states that the emphasis is on genes for which there are no existing databases. Hmmm. It's not clear what that means. Access to information is provided in several ways. One can click on an alphabetized list of genes, use a search engine, or click on a chromosomal map. Most of the clicks I made on the chromosomal map were to genes with no apparent mutation, so it was a bit of a waste of time to use that function. Returned information has maps of mutation info (insertion/deletion, missense, etc.), as well as sequence files, gene descriptions and linked reference information. A very useful site that could be a bit simpler.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »